MicroRNAs and cancer: what we know and what we still have to learn

A report on the Keystone Symposia on MicroRNAs and Cancer, Keystone, Colorado, USA, 10-15 June 2009

The Interaction Between Two Worlds: MicroRNAs and Toll-Like Receptors

MicroRNAs (miRNAs) are critical mediators of posttranscriptional regulation via their targeting of the imperfect antisense complementary regions of coding and non-coding transcripts. Recently, researchers have shown that miRNAs play roles in many aspects of regulation of immune cell function by targeting of inflammation-associated genes, including Toll-like receptors (TLRs). Besides this indirect regulatory role of miRNAs, they can also act as physiological ligands of specific TLRs and initiate the signaling cascade of immune response. In this review, we summarize the potential roles of miRNAs in regulation of TLR gene expression and TLR signaling, with a focus on the ability of miRNAs bind to TLRs

Genetic control of mammalian T-cell proliferation with a synthetic RNA regulatory system - illusion or reality?

Synthetic RNA-based regulatory systems are used to program higher-level biological functions that could be exploited, among many applications, for in vivo diagnostic and therapeutic applications. Chen and colleagues have recently reported a significant technological advance by producing an RNA modular device based on a hammerhead ribozyme and successfully tested its ability to control the proliferation of mammalian T lymphocytes. Like all exciting research, this work raises a lot of significant questions. How quickly will such knowledge be translated into clinical practice? How efficient will this system be in human clinical trials involving adaptive T-cell therapy? We discuss the possible advantages of using such new technologies for specific therapeutic applications

MicroRNA history : discovery, recent applications and next frontiers

We thank the Department of Scientific Publications at The University of Texas MD Anderson Cancer Center for English language editing of the manuscript.Since 1993, when the first small non-coding RNA was identified, our knowledge about microRNAs has grown exponentially. In this review, we focus on the main progress in this field and discuss the most important findings under a historical perspective. In addition, we examine microRNAs as markers ofdisease diagnosis and prognosis, and as new therapeutic targets.M.I.A is supported by a PhD fellowship (SFRH/BD/47031/2008) from FCT (Fundação para a Ciência e Tecnologia) from Portugal. G.A.C. is supported as a Fellow at The University of Texas MD Anderson Research Trust, as a Fellow of The University of Texas System Regents Research Scholar, and by the CLL Global Research Foundation. Work in Dr. Calin’s laboratory was supported in part by NIH, by DoD, by 2009 Seena Magowitz – Pancreatic Cancer Action Network – AACR Pilot Grant and by the U.S./European Alliance for the Therapy of CLL

Ultraconserved Enhancers Roles in Cancer

https://openworks.mdanderson.org/sumexp21/1164/thumbnail.jp

The Genomic and Transcriptomic Landscape of Ultra-Conserved miR-142 in Hematological Malignancies

Department of Translational Molecular Pathology Department of Experimental Therapeutics Department of Translational Molecular Pathology, Department of Experimental Therapeutics, Center for RNA Interference and Non-Coding RNAs, Department of Leukemia, Division of Cancer Medicinehttps://openworks.mdanderson.org/sumexp22/1053/thumbnail.jp

The Involvement of miR-21 in the Molecular Pathogenesis of Richter Transformation

https://openworks.mdanderson.org/sumexp23/1050/thumbnail.jp

MicroRNAs and metastases--the neuroblastoma link

[Excerpt] MicroRNAs (miRNAs) are small noncoding RNAs of approximately 22 nucleotides in length that regulate gene expression post-transcriptionally. These small RNAs are fundamental regulators of several cellular processes, such as differentiation, development, apoptosis, proliferation, cell cycle regulation and metabolism, through the binding to 3' untranslated regions, coding sequence or 5' untranslated regions of target messenger RNAs (mRNAs), preventing their translation or causing their degradation.1 A modest change in only one miRNA will affect multiple mRNA targets; consequently, the deregulation of miRNAs has important consequences to the cellular homeostatic stability, and aberrant miRNAs expression patterns have been described in several types of cancer.2 Recently, miRNAs have been implicated in the metastatic process of several tumors such as human breast and colorectal cancers3 and, as reported this issue of Cancer Biology & Therapy by Guo et al. in neuroblastoma.4 These are extracranial solid tumors, arising from neural crest cells, that are most common in infants and children; metastasis, the main cause of death, is present at the time of diagnosis in approximately 60% of patients. (5) [...